INTRODUCTION AND OBJECTIVES:
The current study is designed to test the hypothesis that prostate biopsy using 68Ga-PSMA PET/Trans Rectal Ultrasound (TRUS) fusion images may have a clinical impact in the subset of patients with a high suspicion of prostate cancer (PCa), a previously negative biopsy and contraindications to or negative multiparametric MRI (mpMRI).
METHODS: This prospective study was performed at a tertiary high volume Hospital in order to use 68Ga-PSMA PET/CT in a selected subgroup of patients for diagnosis of primary PCa: men with persistently elevated PSA and/or PHI (prostate health index) suspicious for PCa, negative digital rectal examination, and at least one negative biopsy (Protocol ICH: MpMRI new-1_2018_emended). The cohort comprised patients with either an equivocal mpMRI (PIRADS v2. 2) or an absolute or relative contraindication to mpMRI. All patients underwent whole body 68Ga-PSMA PET/CT 60 minutes after radiopharmaceutical injection (185-250MBq). Focal PSMA uptake superior to background activity was considered for the analysis and outlined for target biopsy. Semi-quantitative measures for all lesions comprised SUVmax and SUVratio-to-background. Sensitivities, specificities, and accuracy were calculated compared to histopathology results.
RESULTS: Overall, 88 cases were referred to 68Ga-PSMA PET/CT: 66 patients (75%) had already performed mpMRI with either a negative result for PCa (n[28) or positive mpMRI but negative biopsy. In this subset of patients, 54 cases (61%) were addressed to 68Ga-PSMA PET/TRUS fusion biopsy that demonstrated the presence of 33 malignant lesions: 14 cases with GS 6 (3þ3), 19 cases with GS 7 (15 cases GS 3þ4; 4 cases GS 4þ3), and 2 cases GS 10 (5þ5). Mean SUVmax and SUVratio-to-background for PCa lesions resulted statistically significantly higher than in benign lesions (P < 0,001). ROC analysis performed for optimal cut-off points demonstrated that a SUVmax >5.4 and a SUVratio >2.2 could identify clinically significant PCa (GS !7) with an accuracy of 85.9% and 91.5%, respectively. In the subset of patients who had already performed mpMRI, we found instead no correlation between PIRADS and lesions GS, SUVmax or SUVratio-to-background. CONCLUSIONS: Our study confirms and expands previous preliminary findings. In patients with a high suspicion of cancer, despite previously negative biopsy and/or mpMRI, 68Ga-PSMA PET/CT is capable to detect malignant lesions and identify with a high sensitivity clinically relevant PCa. . RN is associated with increased risk of chronic kidney disease, cardiac morbidity, and mortality. In addition, data has shown the oncologic equivalence of PN as treatment for T1a masses. Thus, in 2009, the AUA guideline statement was released, calling for PN to be considered standard of care for T1a renal masses. Despite the guideline changes, many studies have suggested underutilization of PN. We evaluated national trends using the National Cancer Database (NCDB) in the utilization of PN before and after guideline changes.
METHODS: Through the NCDB, we identified 99,035 patients from 2004 to 2015 that underwent surgical resection of T1a (<4.1 cm) renal masses. We evaluated the treatment trends over time and proportion of patients treated with PN or RN based on age, sex, race, income, insurance status, treatment facility volume, and Charlson comorbidity.
RESULTS: Treatment with PN increased from 40.2% in 2004 to 71.3% in 2015 (P<0.001). Older patients were more likely to be treated with RN (HR 1.018, P<0.001), as were those with Charlson score 2 or 3þ (HR 1.288 and 2.074, P<0.001). Patients with lower income were more likely to be treated with RN (HR 1.186, P<0.001) as were uninsured patients (HR 1.108, P[.018) and those treated at low volume centers (HR 1.063, P<0.001). Females were more likely to undergo RN (HR 1.123, P<0.001) as were blacks (HR 1.339, P<0.001). While all of these demographic trends persisted after the release of the AUA guidelines, all HR's decreased except for those for Charlson score and race. Black patients became even more likely to undergo RN (HR 2004 -2009 1.248, HR 2010 -2015 , and in 2015 were over 1.6 times as likely to undergo RN. Patients treated with RN spent more time in the hospital (4.1 days vs. 3.5 days, P<0.001) and had higher overall mortality (17.4% vs. 7.3%, P<0.001).
CONCLUSIONS: Although use of PN for T1a renal masses has increased over time, nearly 30% of patients with T1a masses still underwent RN in 2015. Socioeconomic disparities continue to exist. While most disparities have decreased over time, there has been a concerning increase in use of RN in black patients. 
